Pen injector carry case

Abstract

The present disclosure relates to a pen injector carry case (10, 20, 30) suitable for storing a drug delivery device (1). The carry case (10, 20, 30) comprises a first compartment (13, 23, 33) configured to receive a pen type a drug delivery device (1) and a second compartment (14, 24, 34) configured to receive accessories (2, 3) for the pen type a drug delivery device (1). The carry case (10, 20, 30) is made from two sheets or panels (11, 21, 31, 12, 22, 32) of a high-density polyethylene (HDPE) material that are connected together along seams (15, 25, 35, 16, 26, 36).

Description

[0001] Description

[0002] PEN INJECTOR CARRY CASE

[0003] The present disclosure is generally directed to improvements in sustainability of a pen injector carry case suitable for storing a drug delivery device and e.g. a spare cartridge and / or spare needles within their protective outer packaging.

[0004] Pen type drug delivery devices have application where regular injection by persons without formal medical training occurs. This is increasingly common among patients having e.g. diabetes where self-treatment enables such patients to conduct effective management of their disease. In certain types of drug delivery devices, such as pen type devices, cartridges filled with a liquid drug are used. These cartridges are housed in a cartridge holder or cartridge housing. To dispense a dose of drug from such a cartridge, the drug delivery device has a dose setting and drive mechanism that uses a piston rod or lead screw moving in a distal direction and pressing the bung distally which expels a certain set dose of drug from the cartridge.

[0005] For such devices which provide for self-administration of a medicinal product from a multi-dose cartridge and permit a user to individually set a variable delivery dose, there is a general distinction between devices which are intended to be reused when the cartridge is empty by replacing the empty cartridge by a new cartridge, e.g. a device as disclosed in WO 2014 / 033195 A1 and devices which are intended to be disposed of when the cartridge is empty, e.g. a device as disclosed in EP 1 603 611 B1.

[0006] Users often carry such devices in a carry case which does not only protect the device itself but which also provides space for storing accessory parts, like spare needles within their protective outer packaging and / or, for reusable devices, a spare cartridge. Existing carry cases are often primarily constructed from woven nylon fabric, which has a poor environmental sustainability profile. Further, such carry cases typically consist of a mix

[0007] 16. Dezember 2025 S 100 P 557 WO of different materials, including metal parts for a zipper, different plastic materials, fabric or imitation leather, which are not suitable to be recycled in a common waste stream. An additional drawback of some known carry cases is that they are quite bulky making it difficult to carry them in a trouser or jacket pocket. Examples of carry cases made of plastic or textile materials are described in WO 83 / 04089 A1 , US 2013 / 310802 A1 and US 4,127,155 A. Further, a rigid packaging for a medical device or its accessories is known from US 3,746,155 A or US 2017 / 224435 A1.

[0008] It is an object of the present disclosure to provide an improved carry case for a pen injector that stores and protects at least the device.

[0009] This object is solves with a carry case according to claim 1.

[0010] A pen injector carry case according to the present disclosure is suitable for storing a drug delivery device and accessories and comprises two pockets or compartments. A first compartment is configured to receive a pen type drug delivery device and has an opening suitable for removing the pen type a drug delivery device from the first compartment and a fastener configured to close the opening. A second compartment is configured to receive accessories for the pen type a drug delivery device and has an opening suitable for removing the accessories from the second compartment and a fastener configured to close the opening. According to an aspect of the present disclosure, the carry case is made from or comprises at least two sheets or panels of a high-density polyethylene (HDPE) material, for example made from high-density spunbound polyethylene fibers, that are connected together along one or more seams. The panels may be flaps of a single blank folded over each other along a bending line or may be two separate elements. The carry case according to the present disclosure is a sustainable carry case that stores a pen injector and device accessories constructed from sustainable, soft and / or flexible materials.

[0011] For example, a flexible material manufactured from non-woven HDPE fibres may be used, such as the material with the commercial tradename ‘Tyvek’ available from DuPont. HDPE is known to have a range of properties that make it particularly suitable for a pen injector carry case, it is: lightweight, cost effective, has a good environmental

[0012] 16. Dezember 2025 S 100 P 557 WO sustainability profile (due to its HDPE mono-material), liquid repellent, has good barrier properties, is inert and chemically stable, is durable, printable and can be joined at seams by a heat sealing process (i.e. it does not need to be stitched like many fabrics).

[0013] The carry case according to the present disclosure enables a number of sustainability benefits. For example, non-woven HDPE fibre material has a lower embodied energy than other materials typically used for such cases, e.g. nylon, meaning less energy is used during manufacture, reducing carbon generation. Further, HDPE is already a widely recycled material with established recycling streams, meaning it can potentially be both manufactured using recycled material and can be fed into existing recycling streams post use. The carry case can be made as a ‘mono-material’ product. This simplifies the process for recycling, removing the need for disassembly to separate different material types. This reduces the energy (carbon) used for recycling and increases the quantity of material that may be efficiently recycled. Still further, the carry case is more compact and light-weight than the existing designs, and may be provided in a flattened condition. This enables the size of secondary packaging to be minimised, which can increase the packaging density and efficiency of the supply chain, thereby reducing energy use and carbon in both manufacture and transportation.

[0014] In addition, the use of non-woven HDPE fibre material for construction and a minimisation of components and assembly steps provide significant cost benefits in comparison with current carry case solutions.

[0015] In the carry case according to the present disclosure, the sheets of HDPE material may be bonded together by a heat sealing process to form pockets for the first compartment and the second compartment. Heat sealing the sheets to join seams provides additional cost benefits in comparison with current carry case solutions which often require stitching. As an alternative, the sheets or panels are connected together by an adhesive.

[0016] At least one of the sheets may be a non-woven HDPE fibre material. For example, the sheets may be panels of a high-density spunbound polyethylene fibers material. Further, at least one of the sheets may be transparent or may comprise a transparent panel. For example, a front panel may be transparent to enable user visibility of the carry case

[0017] 16. Dezember 2025 S 100 P 557 WO content. In addition or as an alternative, at least one of the sheets may be opaque or may comprise an opaque panel. For example, an opaque back panel may be used for printing brand or product information, as required.

[0018] According to a further aspect of the present disclosure, at least one of the sheets and / or one of the compartments may comprise an insulating layer and / or a padding layer. For example, a back panel of the carry case may include such a layer, e.g. a LDPE padding to offer some physical protection of the contents while in use. In addition or as an alternative, an insulated lining may be constructed of foil as well as an insulating padding material, such as an LDPE laminate containing sealed air pockets, or similar. An insulating layer may be provided as an insulated lining inside the compartment intended to store accessories, especially a spare cartridge. The insulating layer provides thermal insulation for the content in this compartment. As it is recommended that insulin is stored in a fridge to optimise its longevity, an insulated lining helps to maintain the temperature of the insulin cartridge after the carry case has been removed from the fridge. An insulated lining may also be provided in the first compartment to help prolong the temperature of insulin within the pen Injector device.

[0019] The first compartment and / or the second compartment may be provided as a tubular pocket having a length which exceeds the inner diameter of the pocket. In other words, at least the first compartment which is intended to receive the pen injector device is substantially formed as a sleeve adapted to store an elongate substantially cylindrical body, like a pen type drug delivery device, without to much play. The compartments may be substantially identical in size and shape or may vary in size and / or shape. In an example, the first compartment and the second compartment are arranged substantially parallel to each other separated by a seam running in the length direction of the pockets. In such a side by side arrangement, both pockets or compartments may have the same length.

[0020] In the carry case according to the present disclosure, the first compartment and the second compartment may have a common fastener. In more detail, the fastener may comprises a lid attached to a connecting seam between the sheets which is perpendicular to the length direction of the pockets. In another example, a back panel may extended to form a lid that could be extended to shield a front panel fully or partially. Such a lid feature

[0021] 16. Dezember 2025 S 100 P 557 WO may be retained by an elasticated strap element that may be attached to a connecting seam between the front panel and the back panel. Other methods to retain the lid could be adopted, e.g. a press stud. As a further alternative, the fastener may comprise a ziplock extending perpendicular to the length direction of the pockets. The zip-lock feature may enable both pockets of the carry case to be opened or closed. The zip-lock may be attached to the connecting seam between the front panel and the back panel at the top of the device by heat sealing, or similar bonding process.

[0022] As a further alternative, each compartment may comprise a separate fastener. For example each fastener () comprises a zip-lock extending in the length direction of the pockets. A carry case may include two zip-lock features on either edge that enable the carry case compartments to be individually opened or closed. A longer zip feature extending in the length direction provides improved access to the contents of the carry case.

[0023] According to a further aspect of the present disclosure, the carry case comprises a pen type a drug delivery device in the first compartment, at least one injection needle in the second compartment and at least one cartridge filled with a liquid drug in one of the compartments, e.g. withing the drug delivery device and / or as a separate spare cartridge. In other words, the present disclosure includes a set or an assembly comprising the carry case and at least a pen type drug delivery device, e.g. a drug delivery device as disclosed in WO 2014 / 033195 A1 or in EP 1 603 611 B1.

[0024] The terms “drug” or “medicament” are used synonymously herein and describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients or pharmaceutically acceptable salts or solvates thereof, and optionally a pharmaceutically acceptable carrier. An active pharmaceutical ingredient (“API”), in the broadest terms, is a chemical structure that has a biological effect on humans or animals. In pharmacology, a drug or medicament is used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being. A drug or medicament may be used for a limited duration, or on a regular basis for chronic disorders.

[0025] As described below, a drug or medicament can include at least one API, or combinations thereof, in various types of formulations, for the treatment of one or more

[0026] 16. Dezember 2025 S 100 P 557 WO diseases. Examples of API may include small molecules having a molecular weight of 500 Da or less; polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.

[0027] The drug or medicament may be contained in a primary package or “drug container” adapted for use with a drug delivery device. The drug container may be, e.g., a cartridge, syringe, reservoir, or other solid or flexible vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more drugs. For example, in some instances, the chamber may be designed to store a drug for at least one day (e.g., 1 to at least 30 days). In some instances, the chamber may be designed to store a drug for about 1 month to about 2 years. Storage may occur at room temperature (e.g., about 20°C), or refrigerated temperatures (e.g., from about - 4°C to about 4°C). In some instances, the drug container may be or may include a dual-chamber cartridge configured to store two or more components of the pharmaceutical formulation to-be-administered (e.g., an API and a diluent, or two different drugs) separately, one in each chamber. In such instances, the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components prior to and / or during dispensing into the human or animal body. For example, the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing. Alternatively or in addition, the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body.

[0028] The drugs or medicaments contained in the drug delivery devices as described herein can be used for the treatment and / or prophylaxis of many different types of medical disorders. Examples of disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism. Further examples of disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular

[0029] 16. Dezember 2025 S 100 P 557 WO degeneration, inflammation, hay fever, atherosclerosis and / or rheumatoid arthritis. Examples of APIs and drugs are those as described in handbooks such as Rote Liste 2014, for example, without limitation, main groups 12 (anti-diabetic drugs) or 86 (oncology drugs), and Merck Index, 15th edition.

[0030] Examples of APIs for the treatment and / or prophylaxis of type 1 or type 2 diabetes mellitus or complications associated with type 1 or type 2 diabetes mellitus include an insulin, e.g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms “analogue” and “derivative” refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, by deleting and / or exchanging at least one amino acid residue occurring in the naturally occurring peptide and / or by adding at least one amino acid residue. The added and / or exchanged amino acid residue can either be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues. Insulin analogues are also referred to as "insulin receptor ligands". In particular, the term ..derivative” refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, in which one or more organic substituent (e.g. a fatty acid) is bound to one or more of the amino acids. Optionally, one or more amino acids occurring in the naturally occurring peptide may have been deleted and / or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codea- ble, have been added to the naturally occurring peptide.

[0031] Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Vai or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

[0032] Examples of insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin, Lys(B29) (N- tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-

[0033] 16. Dezember 2025 S 100 P 557 WO palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-pal- mitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)- des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl- des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glu- tamyl)-des(B30) human insulin; B29-N-(w-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(w-carboxyheptadecanoyl) human insulin.

[0034] Examples of GLP-1 , GLP-1 analogues and GLP-1 receptor agonists are, for example, Lixisenatide (Lyxumia®), Exenatide (Exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide which is produced by the salivary glands of the Gila monster), Liraglutide (Vic- toza®), Semaglutide, Taspoglutide, Albiglutide (Syncria®), Dulaglutide (Trulicity®), rEx- endin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide / HM-11260C (Efpegle- natide), HM-15211 , CM-3, GLP-1 Eligen, ORMD-0901, NN-9423, NN-9709, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1 , ZYD-1 , GSK- 2374697, DA-3091 , MAR-701 , MAR709, ZP-2929, ZP-3022, ZP-DI-70, TT-401 (Pega- pamodtide), BHM-034. MOD-6030, CAM-2036, DA-15864, ARI-2651 , ARI-2255, Tir- zepatide (LY3298176), Bamadutide (SAR425899), Exenatide-XTEN and Glucagon- Xten.

[0035] An example of an oligonucleotide is, for example: mipomersen sodium (Kynamro®), a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia or RG012 for the treatment of Alport syndrom.

[0036] Examples of DPP4 inhibitors are Linagliptin, Vildagliptin, Sitagliptin, Denagliptin, Sax- agliptin, Berberine.

[0037] Examples of hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Fol litropi n, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.

[0038] Examples of polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above- mentioned polysaccharides, and / or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight

[0039] 16. Dezember 2025 S 100 P 557 WO heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F 20 (Synvisc®), a sodium hyaluronate.

[0040] The term “antibody”, as used herein, refers to an immunoglobulin molecule or an anti- gen-binding portion thereof. Examples of antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab')2 fragments, which retain the ability to bind antigen. The antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody. In some embodiments, the antibody has effector function and can fix complement. In some embodiments, the antibody has reduced or no ability to bind an Fc receptor. For example, the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region. The term antibody also includes an antigen-binding molecule based on tetravalent bispecific tandem immunoglobulins (TBTI) and / or a dual variable region anti- body-like binding protein having cross-over binding region orientation (CODV).

[0041] The terms “fragment” or “antibody fragment” refer to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and / or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen. Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments. Antibody fragments that are useful in the present invention include, for example, Fab fragments, F(ab')2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigenbinding antibody fragments are known in the art.

[0042] The terms “Complementarity-determining region” or “CDR” refer to short polypeptide sequences within the variable region of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term “framework region” refers to amino acid sequences within the variable region of both heavy

[0043] 16. Dezember 2025 S 100 P 557 WO and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding. Although the framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen.

[0044] Examples of antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).

[0045] Pharmaceutically acceptable salts of any API described herein are also contemplated for use in a drug or medicament in a drug delivery device. Pharmaceutically acceptable salts are for example acid addition salts and basic salts.

[0046] Those of skill in the art will understand that modifications (additions and / or removals) of various components of the APIs, formulations, apparatuses, methods, systems and embodiments described herein may be made without departing from the full scope of the present invention, which encompass such modifications and any and all equivalents thereof.

[0047] An example drug delivery device may involve a needle-based injection system as described in Table 1 of section 5.2 of ISO 11608-1 :2014(E). As described in ISO 11608- 1 :2014(E), needle-based injection systems may be broadly distinguished into multidose container systems and single-dose (with partial or full evacuation) container systems. The container may be a replaceable container or an integrated non-replaceable container.

[0048] As further described in ISO 11608-1 :2014(E), a multi-dose container system may involve a needle-based injection device with a replaceable container. In such a system, each container holds multiple doses, the size of which may be fixed or variable (pre-set by the user). Another multi-dose container system may involve a needle-based injection device with an integrated non-replaceable container. In such a system, each container holds multiple doses, the size of which may be fixed or variable (pre-set by the user). As further described in ISO 11608-1 :2014(E), a single-dose container system may involve a needle-based injection device with a replaceable container. In one example for such a system, each container holds a single dose, whereby the entire deliverable volume is expelled (full evacuation). In a further example, each container holds a single dose, whereby a portion of the deliverable volume is expelled (partial evacuation). As

[0049] 16. Dezember 2025 S 100 P 557 WO also described in ISO 11608-1 :2014(E), a single-dose container system may involve a needle-based injection device with an integrated non-replaceable container. In one example for such a system, each container holds a single dose, whereby the entire deliverable volume is expelled (full evacuation). In a further example, each container holds a single dose, whereby a portion of the deliverable volume is expelled (partial evacuation).

[0050] In the following, non-limiting, examples of a carry case for a drug delivery device are described in more detail by making reference to the drawings, in which:

[0051] Figure 1 shows a front view of a carry case according to a first example of the present disclosure;

[0052] Figure 2 shows a side view of the carry case of Figure 1 ;

[0053] Figure 3 shows a perspective view of the carry case of Figure 1 ;

[0054] Figure 4 shows a front view of a carry case according to a second example of the present disclosure;

[0055] Figure 5 shows a side view of the carry case of Figure 4;

[0056] Figure 6 shows a perspective view of the carry case of Figure 4;

[0057] Figure 7 shows a front view of a carry case according to a third example of the present disclosure;

[0058] Figure 8 shows a side view of the carry case of Figure 7; and

[0059] Figure 9 shows a perspective view of the carry case of Figure 7.

[0060] 16. Dezember 2025 S 100 P 557 WO Figures 1 to 3 show a first example of a carry case 10 for a pen type drug delivery device 1 and accessories for the drug delivery device, here a spare cartridge 2 and spare needles 3 within their protective outer packaging.

[0061] The carry case 10 is constructed principally from two sheets, namely a front panel 11 and a back panel 12, of non-woven HDPE fibre material that are bonded together by a heat sealing process to form two pockets or compartments 13, 14, one for the pen type drug delivery device 1 , and the other for a spare cartridge 2 and up to three spare needles 3 within their protective outer packaging. The compartments 13, 14 are substantially tubular and may have an at least partially cylindrical shape as depicted which fits to the substantially cylindrical shape of the pen type drug delivery device 1 and its accessories 2, 3. The compartments 13, 14 are forms by a bonding process, especially achieved by heat sealing. However, other approaches could be adopted (e.g. adhesive). The heat sealing joins the sheets or panels 11 , 12 along longitudinal seams 15 (extending in a length direction which may correspond to the longitudinal axis of the drug delivery device 1) and one or more transverse seams 16 (extending substantially perpendicular to the length direction). The seams 15, 16 are arranged such that the pockets or compartments 13, 14 each have an opening on one edge (on the upper side as seen in Figure 1) which may be closed by a fastener.

[0062] The front panel 11 may be transparent to enable user visibility of the carry case content. The back panel 12 may be opaque and is extended to form a lid 17 that could be extended to shield the whole of the transparent front panel 11 , if required. The lid 17 forms a fastner configured to close the openings of both pockets or compartments 13, 14. The back panel 12 may be used for printing brand or product information, as required.

[0063] In this example, the lid 17 is retained by an elasticated strap 18, that is attached to the longitudinal connecting seams 15 between the front panel 11 and back panel 12. Other methods to retain the lid 17 could be adopted, e.g. a press stud.

[0064] The flexible carry case 20 of the second example depicted in Figures 4 to 6 shares several attributes with the carry case 10 of the first example. It is constructed principally from two sheets or panels 21 , 22 of non-woven HDPE fibre material forming two compartments

[0065] 16. Dezember 2025 S 100 P 557 WO 23, 24. The sheets or panels 21 , 22 are bonded together along heat sealing seams 25, 26. The carry case 20 may include a transparent front panel 21 to enable user visibility of the contents. It may include some opaque sections, e.g. the back panel 22, that may be used for branding or product information.

[0066] The back panel 22 in this second example includes a LDPE padding to offer some physical protection of the contents while in use.

[0067] The second example of the carry case 20 includes a zip-lock feature 27 as a common fastener that enables the openings of both pockets of the carry case 20 to be opened or closed. The zip-lock 27 is attached to the connecting seams 25 between the front panel 21 and back panel 22 at the top of the device by heat sealing, or similar bonding process. Again, other methods for opening and closing could be adopted.

[0068] The flexible carry case 30 of the third example depicted in Figures 7 to 9 shares several attributes with the carry case 10 of the first example and with the carry case 20 of the second example. It is constructed principally from two sheets of non-woven HDPE that are bonded together. It may include some transparent panels, e.g. front panel 31 as depicted, to enable user visibility of the contents. It may include some opaque panels, e.g. back panel 32 as depicted, that may be used for branding or product information. Two compartments 33, 34 are defined by heat sealing seams 35, 36.

[0069] The right compartment 34 as seen in Figure 7 includes an insulated lining that provides thermal insulation for the content in this compartment 36. It is recommended that, e.g. insulin, is stored in stored in a fridge, to optimise its longevity. The insulated lining helps to maintain the temperature of the insulin cartridge after the carry case 30 has been removed from the fridge. The insulated lining may be constructed of foil as well as an insulating padding material, such as an LDPE laminate containing sealed air pockets (i.e. bubble wrap), or similar. An insulated lining could also be provided in the left compartment 33, to help prolong the temperature of insulin within the pen type drug delivery device 1.

[0070] 16. Dezember 2025 S 100 P 557 WO This example includes two zip-lock features 37 on either edge as fasteners that enable the openings of carry case 30 compartments 33, 34 to be individually opened or closed. The longer zip features 37 (compared to the zip-lock 27 of the second example) provides improved access to the contents 33, 34 of the carry case 30. The feature is constructed in the same way as in the second example.

[0071] It is a common feature of all three examples that at least two sheets or panels of a nonwoven high-density spunbound polyethylene fibers material are connected, preferably by heat sealing, to form at least two compartments or pockets in the carry case, each having an opening which may be closed by a fastener. The sheets or panels may be flaps of a single blank folded over each other along a bending line or may be two separate elements. This material has the benefit of being lightweight, durable and breathable, yet resistant to water, abrasion, bacterial penetration and aging. In addition, this material has sustainability benefits, like lower embodied energy than other materials typically used for such cases, e.g. nylon, being a widely recycled material with established recycling streams and / or being a mono-material product (including optional insulation layers made of LDPE). On the other hand, the present disclosure is not limited to a specific design of transparent and / or opaque portions of the carry case. A padding or insulating layer may be provided in at least one pocket or compartment. Various methods for opening and closing could be adopted as exemplary described with respect to Figures 1 to 9.

[0072] 16. Dezember 2025 S 100 P 557 WO Reference Numerals

[0073] 1 drug delivery device 22 back panel (sheet)

[0074] 2 cartridge 23 first compartment (pocket)

[0075] 3 needle 24 second compartment (pocket)

[0076] 25 longitudinal seam

[0077] 10 carry case 26 transversal seam

[0078] 11 front panel (sheet) 27 zip-lock (fastener)

[0079] 12 back panel (sheet)

[0080] 13 first compartment (pocket) 30 carry case

[0081] 14 second compartment (pocket) 31 front panel (sheet)

[0082] 15 longitudinal seam 32 back panel (sheet)

[0083] 16 transversal seam 33 first compartment (pocket)

[0084] 17 lid (fastener) 34 second compartment (pocket)

[0085] 18 strap 35 longitudinal seam

[0086] 36 transversal seam

[0087] 20 carry case 37 zip-lock (fastener)

[0088] 21 front panel (sheet)

[0089] 16. Dezember 2025 S 100 P 557 WO

Claims

Claims1. A pen injector carry case suitable for storing a drug delivery device (1 ), wherein the carry case (10, 20, 30) comprises a first compartment (13, 23, 33) configured to receive a pen type drug delivery device (1 ), the first compartment (13, 23, 33) having an opening suitable for removing the pen type a drug delivery device (1 ) from the first compartment (13, 23, 33) and a fastener (17, 27, 37) configured to close the opening of the first compartment (13, 23, 33), characterized in that the carry case (10, 20, 30) further comprises a second compartment (14, 24, 34) configured to receive accessories (2, 3) for the pen type a drug delivery device (1 ), the second compartment (14, 24, 34) having an opening suitable for removing the accessories (2, 3) from the second compartment (14, 24, 34) and a fastener (17, 27, 37) configured to close the opening of the second compartment (14, 24, 34), wherein the carry case (10, 20, 30) is made from at least two panels (11 , 21 , 31 , 12, 22, 32) of a high-density polyethylene (HDPE) material that are connected together along seams (15, 25, 35, 16, 26, 36).

2. The carry case according to claim 1 , wherein at least two panels (11 , 21 , 31 , 12, 22, 32) of high-density polyethylene (HDPE) material bonded together by a heat sealing process to form the first compartment (13, 23, 33) and the second compartment (14, 24, 34).

3. The carry case according to claim 1 or 2, wherein at least one of the panels (11 , 21 , 31 , 12, 22, 32) is a non-woven high-density polyethylene (HDPE) fibre material.

4. The carry case according to any one of the preceding claims, wherein at least one of the panels (11 , 21 , 31 , 12, 22, 32) is a high-density spunbound polyethylene fibers material.

5. The carry case according to any one of the preceding claims, wherein at least one of the panels (11 , 21 , 31 , 12, 22, 32) is a transparent panel (1 1 , 21 , 31 ).

16. Dezember 2025 S 100 P 557 WO6. The carry case according to any one of the preceding claims, wherein at least one of the panels (11 , 21 , 31 , 12, 22, 32) is an opaque panel (12, 22, 32).

7. The carry case according to any one of the preceding claims, wherein at least one of the panels (11 , 21 , 31 , 12, 22, 32) and / or one of the compartments (13, 23, 33, 14, 24, 34) comprises an insulating layer and / or a padding layer.

8. The carry case according to any one of the preceding claims, wherein the first compartment (13, 23, 33) and the second compartment (14, 24, 34) are tubular pockets each having a length which exceeds the inner diameter of the pockets.

9. The carry case according to claim 8, wherein the first compartment (13, 23, 33) and the second compartment (14, 24, 34) are arranged substantially parallel to each other separated by a seam (15, 25, 35) running in the length direction of the pockets.

10. The carry case according to any one of the preceding claims, wherein the first compartment (13, 23, 33) and the second compartment (14, 24, 34) comprise a common fastener (17, 27).11 . The carry case according to claims 9 and 10, wherein the fastener comprises a lid (17) attached to a connecting seam (16) between the panels (11 , 21 , 31 , 12, 22, 32) which is perpendicular to the length direction of the pockets.

12. The carry case according to claims 9 and 10, wherein the fastener comprises a zip-lock (27) extending perpendicular to the length direction of the pockets.

13. The carry case according to any one of claims 1 to 9, wherein each compartment (13, 23, 33, 14, 24, 34) comprises a separate fastener (37).

14. The carry case according to claims 9 and 13, wherein each fastener comprises a zip-lock (37) extending in the length direction of the pockets.

16. Dezember 2025 S 100 P 557 WO15. The carry case according to any one of the preceding claims comprising a pen type a drug delivery device (1 ) in the first compartment (13, 23, 33), at least one injection needle (3) in the second compartment (14, 24, 34) and at least one cartridge (2) filled with a liquid drug in one of the compartments (13, 23, 33, 14, 24, 34).

16. Dezember 2025 S 100 P 557 WO

Images